Three months ago Evolus delivered the quarter its bulls had been waiting for: 21% revenue growth, the first full-year guidance raise of the cycle, and a filler market that finally turned positive after two years of decline. The stock barely reacted, and sentiment has since soured. That leaves the third-quarter report, due after the close on November 4, with a clear job. It has to show that the acceleration was the start of a trend and not a one-quarter spike.
The Street is looking for revenue of about $77.1 million, up 11.8% from $69.0 million a year ago, and a non-GAAP loss of $0.05 per share. The Earnings Whisper sits a couple of cents better at a $0.03 loss. That is a modest gap, but it hints that some investors expect the operating leverage seen last quarter to carry forward. Revenue growth near 12% would mark a noticeable step down from the second quarter, though the comparison is distorted by seasonality. The third quarter is typically the lightest of the year, and last year's version grew 13%. The more telling issue is what the quarter implies for the rest of 2026.
Management now guides full-year revenue to $330 million to $337 million, having lifted the low end from $327 million. Consensus of roughly $330 million sits right at the floor of that range, a sign that analysts did not fully accept the raise. With first-half revenue of about $157 million, hitting the guidance midpoint requires roughly $176 million in the back half. If the third quarter lands near $77 million, the fourth quarter would need to approach $99 million, about 10% above last year's $90.3 million. A third-quarter beat would ease that burden considerably, while a miss would push the burden onto the holiday quarter, when two new toxin competitors from AbbVie and Galderma are expected to be in the market.
The operating details matter as much as the top line. Management described the U.S. toxin market as growing at a mid-single-digit pace, faster than it had expected, and said the filler category had returned to growth. Evidence that Evelisse kept building on its more than $2 million sequential gain, and that the portfolio bundle continues driving filler adoption well above the roughly 25% baseline penetration, would support the idea that Evolus is becoming a multi-product aesthetics company rather than a single-toxin challenger. Early commentary on the Esteem launch in Europe and the Cimetase push into Canada, Australia and New Zealand would add color, though neither should move the numbers much yet.
Margins deserve scrutiny. Second-quarter gross margin got about 120 basis points from a one-time tariff refund, and the underlying first-half margin was flat year over year. Management nonetheless raised full-year adjusted gross margin guidance to 67.0% to 67.5%, so a clean quarter near that band without help from refunds would be reassuring. A fourth straight quarter of positive adjusted EBITDA would also matter, particularly with cash having slid to $45.2 million from $53.8 million at year-end. Any further drain, or new tariff pressure on Jeuveau, would revive balance-sheet questions.
The stock is up 2.6% since the last report, edging out a slightly negative S&P 500, and trades at $7.17, above its 200-day average of $6.22 but well below its post-earnings peak of $9.31. Sentiment has slipped from mildly bearish to more clearly bearish. That combination suggests the market gave back an early rally and remains unconvinced. The central question is simple: can Evolus post growth and margins that keep the raised outlook credible heading into a more competitive fourth quarter? If it can, the low expectations embedded in consensus look too conservative. If not, the inflection story starts to look premature.